NDAORALTABLET, EXTENDED RELEASE
Approved
Jan 1992
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
14
Data completeness
4/8 — Partial
TOPROL-XL (metoprolol succinate) by CorMedix is 1 -selective (cardioselective) adrenergic receptor blocking agent. Approved for hypertension, heart failure, cardiomyopathy. First approved in 1992.
Drug data last refreshed Yesterday · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TOPROL-XL is a cardioselective beta-1 adrenergic receptor blocker (extended-release metoprolol succinate) approved for hypertension, heart failure, and cardiomyopathy. It reduces cardiac workload and oxygen demand by slowing heart rate and decreasing contractility, while maintaining preferential selectivity for cardiac beta-1 receptors over bronchial beta-2 receptors at therapeutic doses.
LOE Approaching
As a LOE-approaching generic small molecule, TOPROL-XL faces declining revenue and likely smaller commercial infrastructure, signaling potential team consolidation or transition to generic-focused maintenance roles.
Mechanism of Action
1 -selective (cardioselective) adrenergic receptor blocking agent. This preferential effect is not absolute, however, and at higher plasma concentrations, metoprolol also inhibits beta 2 -adrenoreceptors, chiefly located in the bronchial and vascular musculature. Metoprolol has no intrinsic…
Indications (3)
Worked on TOPROL-XL at CorMedix? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.